An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

Novartis Pharmaceuticals34 enrolled

Overview

This study was designed to evaluate the efficacy and safety of zoledronic acid compared to placebo in osteoporotic children treated with glucocorticoids

In March 2017, Novartis stopped enrollment as the study was not feasible to be conducted due to low enrollment and other recruitment challenges. Patients receiving the treatment continued to receive the treatment per protocol.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Osteoporosis

Interventions

Zoledronic acidDRUG

intravenous infusion

PlaceboDRUG

intravenous infusion

Eligibility

Sex: ALLMin age: 5 YearsMax age: 17 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * A diagnosis of chronic rheumatologic conditions or inflammatory bowel disease or Duchenne muscular dystrophy requiring systemic glucocorticoids (i.v. or oral) within 12 months prior to screening * Lumbar Spine BMDZ-score of -0.5 or worse * Evidence of at least at least 1 vertebral compression fracture of Genant Grade 1 or higher (or radiographic signs of vertebral fracture) within 1 month from Screening visit OR One or more, low-trauma, lower extremity long-bone fracture which occurred sometime within the 2 years PRECEDING enrollment in the study OR Two or more, low-trauma, upper extremity long-bone fractures which occurred sometime within the 2 years PRECEDING enrollment in the study * Consent/assent to study participation Key Exclusion Criteria: * History of primary bone disease (OI, Idiopathic Juvenile Osteoporosis, Rickets/Osteomalacia) * Any medical condition that might have interfered with the evaluation of lumbar spine BMD, such as severe scoliosis or spinal fusion. Patients with less than 3 evaluable vertebrae by Dual Energy X-ray Absorptiometry (DXA) evaluation in the region of interest lumbar 1 (L1) to lumbar 4 (L4), * Hypocalcemia and hypophosphatemia * Serum 25-hydroxy vitamin D concentrations of \<20 ng/mL or \<50 nmol/L * estimated glomerular filtration rate (GFR) \<60 mL/min/1.73 m2 * serum creatinine increase between Visit 1 and Visit 2 \>0.5 mg/dL (44.2 μmol/L) * Uncontrolled symptoms of cardiac failure or arrhythmia * Any prior use of bisphosphonates, or high dose sodium fluoride

Locations (12)

Novartis Investigative Site

Westmead, New South Wales, Australia

Novartis Investigative Site

Vancouver, British Columbia, Canada

Novartis Investigative Site

Winnipeg, Manitoba, Canada

Outcomes

Primary Outcomes

Mean Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score at Month 12

Lumbar Spine Bone Mineral Density (BMD) Z-score was determined by the central imaging vendor before first treatment and at Month 12. The methods to be used to measure Lumbar Spine BMD Z-score were described in the respective DXA Manuals provided by central imaging vendor. Positive changes from baseline indicated an improvement in condition.

Time frame: Month 12

Secondary Outcomes

Mean Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score at Month 6

Lumbar Spine Bone Mineral Density (BMD) Z-score was determined by the central imaging vendor before first treatment and at Month 6. The methods to be used to measure Lumbar Spine BMD Z-score were described in the respective DXA Manuals provided by central imaging vendor. Positive changes from baseline indicated an improvement in condition.

Time frame: Month 6

Mean Change From Baseline in Lumbar Spine BMC at Month 6 and 12

Lumbar Spine BMC was determined by the central imaging vendor before first treatment and at Months 6 and 12. The methods to be used to measure BMC were described in the respective DXA Manuals.

Time frame: Month 6, Month 12

Mean Change From Baseline in Total Body BMC at Month 6 and 12

Total body BMC was all determined by the central imaging vendor before first treatment and at Months 6 and 12. The methods to be used to measure BMC were described in the respective DXA Manuals.

Time frame: Month 6, Month 12

Mean Change From Baseline in Serum P1NP at Months 6 and 12

Serum Procollagen type 1 amino-terminal propeptide (P1NP) was collected before first treatment (baseline) and at Months 6 and Month 12 according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Novartis Investigative Site

Ottawa, Ontario, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Budapest, Hungary

Novartis Investigative Site

Moscow, Russia

Novartis Investigative Site

Saint Petersburg, Russia

Novartis Investigative Site

Soweto, Gauteng, South Africa

...and 2 more locations

Time frame: Month 6, Month 12

Mean Change From Baseline in BSAP at Months 6 and 12

Bone specific alkaline phosphatase (BSAP) were collected before first treatment (baseline) and at Months 6 and Month 12 according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory.

Time frame: Month 6, Month 12

Mean Change From Baseline in Serum NTX at Months 6 and 12

Serum Cross linked N-telopeptide (NTX) were collected before first treatment (baseline) and at Months 6 and Month 12 according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory.

Time frame: Month 6, Month 12

Mean Change From Baseline in Serum TRAP-5b at Months 6 and 12

Serum Tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) was collected before first treatment (baseline) and at Months 6 and Month 12 according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory.

Time frame: Month 6, Month 12

Number of Participants With New Vertebral Fractures at Month 12

New vertebral fractures were defined as fractures of Genant Grade 1 or higher that occurred at lumbar or thoracic spine from first dose infusion to the end of the study.

Time frame: Month 12

Mean Change From Baseline in Vertebral Morphometry at Month 12

Vertebral morphometry (or concave index) was calculated using the average ratio between mid-height and posterior height from L1 to L4 and performed by a central reader.

Time frame: Month 12

Percentage of Patients With Reduction in Pain at Months 3, 6, 9 and 12

Pain was evaluated at each visit (in office and telephone visit) at randomization, Months 3, 6, 9 and 12 using the Faces Pain Scale-Revised (FPS-R). Children were selecting the face that best fits their pain. The pain score ranged from 0 (No Pain) to 10 (Very Much Pain). The reduction in pain from baseline by visit was evaluated based on whether or not patients had a decrease in their FPS-R from baseline. If pain remained the same or worsened from baseline a patient was classified as '0' and if the pain scale decreased then the patient was classified as '1'.

Time frame: Month 3, Month 6, Month 9 and Month 12

Mean Change From Baseline in 2nd Metacarpal Cortical Width at Month 12

Left posteroanterior (PA) hand/wrist X-ray were taken at Visit 1 and at the Month 12 visit to assess bone age and the between-treatment differences for change in 2nd metacarpal cortical width at Month 12 relative to baseline. If a fracture of the left upper extremity precluded radiographic imaging, then the right hand was evaluated for this purpose. In this case, the right hand was be imaged at both Visit 1 and at Month 12. The information was used in the assessment of bone density.

Time frame: Month 12

Urinary Concentration of Zoledronic Acid at Month 12

Urine was collected overnight or for at least 4 waking hours from all patients able to provide specimens, to measure urinary concentration of zoledronic acid at Month 12. Only descriptive analysis done.

Time frame: Month 12

Safety of Zoledronic Acid for the Treatment of Osteoporotic Children Treated With Glucocorticoids

Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that zoledronic acid is safe for the treatment of osteoporotic children treated with glucocorticoids through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive analysis done.

Time frame: Baseline through Month 12